5.59% -0.0074

Petros Pharmaceuticals Inc (PTPI)

Überblick Nachrichten Preisverlauf Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Petros Pharmaceuticals Inc Stock (PTPI) Company Profile

Petros Pharmaceuticals Inc

Healthcare (1169)

973-242-0005

1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK

Nächster Verdiensttermin

Neueste SEC-Einreichungen

PTPI's Discussions on Twitter

Vergleichen Sie PTPI mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
PTPI Petros Pharmaceuticals Inc	0.125	1.41M	4.02M	-4.73M	-5.85M	-4.21
ZTS Zoetis Inc	160.46	71.85B	9.26B	2.49B	2.30B	5.47
HLN Haleon Plc Adr	10.08	45.58B	14.26B	1.55B	0	0.3383
TAK Takeda Pharmaceutical Co Adr	14.06	44.58B	30.25B	1.37B	5.08B	0.4257
TEVA Teva Pharmaceutical Industries Ltd Adr	16.74	19.18B	16.54B	-1.64B	749.00M	-1.45
ITCI Intra Cellular Therapies Inc	128.60	13.67B	612.78M	-86.37M	-62.91M	-0.87

Petros Pharmaceuticals Inc Aktie (PTPI) Neueste Nachrichten

Finanzdaten der Petros Pharmaceuticals Inc-Aktie (PTPI)

Petros Pharmaceuticals Inc (PTPI)

Petros Pharmaceuticals Inc Stock (PTPI) Company Profile

Vergleichen Sie PTPI mit anderen Aktien

Petros Pharmaceuticals Inc Aktie (PTPI) Neueste Nachrichten

Form 424B4 Petros Pharmaceuticals, - StreetInsider.com

PTPI stock plunges to 52-week low of $0.15 amid market challenges - Investing.com India

Crude Oil Gains 1.5%; Fluor Shares Plunge Following Downbeat Earnings - Benzinga

Watsco, Septerna, Nike - TradingView

Petros Pharmaceuticals announces pricing of $9.6 million public offering - MSN

Petros Pharmaceuticals Prices $9.6 Million Public Offering of Shares, Warrants -February 18, 2025 at 09:52 am EST - Marketscreener.com

US Stocks Mixed; NY State Business Activity Rises In February - Benzinga

Petros Pharmaceuticals sets public offering at $0.24 per share - Investing.com

Petros Pharmaceuticals prices 40M shares at 24c in public offering - TipRanks

Petros Pharmaceuticals Announces Pricing of $9.6 Million Public Offering of Common Stock and Warrants - ACCESS Newswire

Major Capital Raise: Petros Pharmaceuticals Locks $9.6M Financing DealStrategic Move or Dilution Risk? - StockTitan

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga

Petros Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference - ACCESS Newswire

Best Penny Stocks for Today (Charts Updated Daily) - Benzinga

Petros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software Provider - ACCESS Newswire

Petros Pharmaceuticals (NASDAQ:PTPI) Trading 5.2% Higher – Still a Buy? - Defense World

Erectile Dysfunction Treatment Drugs Market to Hit USD 5.97 Billion by 2032, Growing at a 6.84% CAGR - EIN News

Analytical Lens: Exploring Perella Weinberg Partners (PWP)’s Financial Story Through Ratios - The Dwinnex

Balance Sheet Breakdown: Petros Pharmaceuticals Inc (PTPI)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex

Petros Pharmaceuticals Inc’s (PTPI) Stock: A Week-by-Week Analysis - The News Heater

Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil) - ACCESS Newswire

Petros Pharmaceuticals Strategically Positioned to Benefit as Technology Leader from Newly Approved FDA OTC Final Rules - ACCESS Newswire

Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) (avanafil) the First Erectile Dysfunction Medication to Achieve OTC Status - ACCESS Newswire

Johnson & Johnson posts Q4 beat as drug sales offset MedTech weakness - MSN

Petros Pharmaceuticals modifies terms with investors By Investing.com - Investing.com India

Harmony Biosciences chief commercial officer sells shares worth $1.15m - MSN

Microvast files for $250M mixed securities shelf offering - MSN

Proprietary Technology Addressing the Rx-to-OTC Switch Self-Care Market Valued at over $38 Billion annually - ACCESS Newswire

Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor’s (rosuvastatin) OTC Switch Technology Provider - ACCESS Newswire

Janbelco BV trims stake in Thalassa Holdings - MSN

Immedica to buy Marinus Pharmaceuticals for $151m - MSN

XORTX Therapeutics Announces Auditor Transition - MSN

Apellis Pharmaceuticals executive sells $36,998 in stock - MSN

Amneal gets FDA approval for generic Byetta, resubmits DHE NDA - MSN

Pharming Group appoints former Novartis USA President Fabrice Chouraqui as New CEO - MSN

Takeda-backed Ascentage Pharma targets $1.75 billion valuation in US IPO - MSN

Vincerx Pharma enters at-the-market equity offering deal - MSN

Mitsubishi Chemical picks Bain as preferred bidder for pharma unit, sources say - MSN

Sanofi receives GMP warning letter for Genzyme facility - MSN

Sinopharm Accord Projects Notable Profit Decline for 2024 - MSN

Comparing Petros Pharmaceuticals (NASDAQ:PTPI) & MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World

AstraZeneca's Calquence gains FDA nod for 1L MCL treatment - MSN

FDA grants tentative approval for Amneal generic of Bausch Health's Xiafan - MSN

GoodRx Holdings announces CFO resignation; shares drop - MSN

Petronas may cut capex up to RM10b after Petro gas deal - The Malaysian Reserve

5 Best-performing Canadian Pharma Stocks (Updated January 2025) - MSN

Pre-market Movers: SANA, SLDB, JSPR, DRIO... - RTTNews

AMRN Stock Rises Over 5% Amidst Lack of Institutional Ratings - GuruFocus.com

GROUPIRA Co-Founder Petros Koumantaros Appointed to Washington Saves Governing Board - Yahoo Finance

Pre-market Movers: ONCO, COEP, NUVB, SPRC... - RTTNews

Psychedelic Drug Therapy May Address Mental Health Concerns in People with Cancer & Addiction - NYU Langone Health

Finanzdaten der Petros Pharmaceuticals Inc-Aktie (PTPI)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie PTPI